English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Correspondence: Dr Vingerling, Department of Ophthalmology, Erasmus Medical Center, PO Box 2040, 3000CA Rotterdam, the Netherlands (j.vingerling @erasmusmc.nl). Financial Disclosure: None reported. Funding/Support: This study was supported by unrestricted grants from GlaxoSmithKline and Topcon Europe BV and by grants from the following institutions: Netherlands Organization for Scientific Research, Blindenhulp, and OOG, the Hague, the Netherlands; Optimix, Blindenpenning, and Prins Bernhard Cultuurfonds, Amsterdam, the Netherlands; Neyenburgh, Bunnik, the Netherlands; Physico Therapeutic Institute, Swart van Essen, Sint Laurens Institute, Bevordering van Volkskracht, Rotterdamse Blindenbelangen Association, and Van Leeuwen Van Lignac, Rotterdam, the Netherlands; kfHein, Utrecht, the Netherlands; and Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Doorn, the Netherlands. Role of the Sponsor: The sponsors or funding organizations had no involvement in the design or conduct of this research. Additional Contributions: Yun-Fu Hu and Rena Vora, GlaxoSmithKline, developed the high-throughput radiometric activity assay for Lp-PLA2.

Relentless Placoid Chorioretinitis Associated With Central Nervous System Lesions Treated With Mycophenolate Mofetil